表紙:ヒトマイクロバイオーム治療薬の世界市場(2021年~2025年)
市場調査レポート
商品コード
1036445

ヒトマイクロバイオーム治療薬の世界市場(2021年~2025年)

Global Human Microbiome Therapeutics Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
ヒトマイクロバイオーム治療薬の世界市場(2021年~2025年)
出版日: 2021年08月30日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のヒトマイクロバイオーム治療薬の市場規模は、2021年から2025年の予測期間に47.79%のCAGRで成長し、5億1,608万米ドルに成長すると予測されています。

同市場を牽引する要因には、慢性疾患の有病率の高まりと堅調なパイプラインなどが挙げられます。

当レポートでは、ヒトマイクロバイオーム治療薬の世界市場を調査し、市場規模や予測、市場の促進要因および課題、市場機会、アプリケーション・地域別の市場分析、ベンダー情勢、主要ベンダー分析などの体系的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模(2020年)
  • 市場規模予測(2020年~2025年)

ファイブフォース分析

  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

アプリケーション別、市場セグメンテーション

  • 市場セグメンテーション
  • アプリケーション別の比較
  • 胃腸障害
  • 感染症
  • その他
  • アプリケーション別の市場機会

顧客情勢

地域別、市場セグメンテーション

  • 地域別セグメンテーション
  • 地域別比較
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 地域情勢別の市場機会
  • 市場の推進力
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • 創造的破壊の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

付録

目次
Product Code: IRTNTR43730

Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by $ 516.08 mn during 2021-2025, progressing at a CAGR of 47.79% during the forecast period. Our report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, the growing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The human microbiome therapeutics market analysis includes the application segment and geographic landscape.

Technavio's human microbiome therapeutics market is segmented as below:

By Application

  • Gastrointestinal disorders
  • Infectious diseases
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the side effects of existing treatmentas one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on human microbiome therapeutics market covers the following areas:

  • Human microbiome therapeutics market sizing
  • Human microbiome therapeutics market forecast
  • Human microbiome therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • Gastrointestinal disorders - Market size and forecast 2020-2025
    • Infectious diseases - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • 4D pharma Plc
    • ENTEROME SA
    • Ferring B.V.
    • Johnson and Johnson Inc.
    • Kaleido Biosciences Inc.
    • OptiBiotix Health Plc
    • PureTech Health Plc
    • Second Genome Therapeutics
    • Seres Therapeutics Inc.
    • Takeda Pharmaceutical Co. Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Gastrointestinal disorders - Market size and forecast 2020-2025 ($ million)
  • 24: Gastrointestinal disorders - Year-over-year growth 2020-2025 (%)
  • 25: Infectious diseases - Market size and forecast 2020-2025 ($ million)
  • 26: Infectious diseases - Year-over-year growth 2020-2025 (%)
  • 27: Others - Market size and forecast 2020-2025 ($ million)
  • 28: Others - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Application
  • 30: Customer landscape
  • 31: Market share By Geographical Landscape 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity By Geographical Landscape ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: 4D pharma Plc - Overview
  • 50: 4D pharma Plc - Product and service
  • 51: 4D pharma Plc - Key offerings
  • 52: 4D pharma Plc - Key customers
  • 53: 4D pharma Plc - Segment focus
  • 54: ENTEROME SA - Overview
  • 55: ENTEROME SA - Product and service
  • 56: ENTEROME SA - Key offerings
  • 57: ENTEROME SA - Key customers
  • 58: ENTEROME SA - Segment focus
  • 59: Ferring B.V. - Overview
  • 60: Ferring B.V. - Product and service
  • 61: Ferring B.V. - Key offerings
  • 62: Ferring B.V. - Key customers
  • 63: Ferring B.V. - Segment focus
  • 64: Johnson and Johnson Inc. - Overview
  • 65: Johnson and Johnson Inc. - Business segments
  • 66: Johnson and Johnson Inc. - Key offerings
  • 67: Johnson and Johnson Inc. - Key customers
  • 68: Johnson and Johnson Inc. - Segment focus
  • 69: Kaleido Biosciences Inc. - Overview
  • 70: Kaleido Biosciences Inc. - Product and service
  • 71: Kaleido Biosciences Inc. - Key offerings
  • 72: Kaleido Biosciences Inc. - Key customers
  • 73: Kaleido Biosciences Inc. - Segment focus
  • 74: OptiBiotix Health Plc - Overview
  • 75: OptiBiotix Health Plc - Product and service
  • 76: OptiBiotix Health Plc - Key offerings
  • 77: OptiBiotix Health Plc - Key customers
  • 78: OptiBiotix Health Plc - Segment focus
  • 79: PureTech Health Plc - Overview
  • 80: PureTech Health Plc - Business segments
  • 81: PureTech Health Plc - Key offerings
  • 82: PureTech Health Plc - Key customers
  • 83: PureTech Health Plc - Segment focus
  • 84: Second Genome Therapeutics - Overview
  • 85: Second Genome Therapeutics - Product and service
  • 86: Second Genome Therapeutics - Key offerings
  • 87: Second Genome Therapeutics - Key customers
  • 88: Second Genome Therapeutics - Segment focus
  • 89: Seres Therapeutics Inc. - Overview
  • 90: Seres Therapeutics Inc. - Product and service
  • 91: Seres Therapeutics Inc. - Key offerings
  • 92: Seres Therapeutics Inc. - Key customers
  • 93: Seres Therapeutics Inc. - Segment focus
  • 94: Takeda Pharmaceutical Co. Ltd. - Overview
  • 95: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 96: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 97: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 98: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations